Concepts (37)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2019 | 21 | 0.320 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2019 | 46 | 0.310 |
Why?
|
| Sulfonamides | 2 | 2019 | 126 | 0.290 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 22 | 0.240 |
Why?
|
| Mediastinal Neoplasms | 1 | 2025 | 20 | 0.240 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2025 | 68 | 0.230 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 96 | 0.220 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2025 | 87 | 0.220 |
Why?
|
| Oncologists | 1 | 2023 | 19 | 0.210 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 170 | 0.210 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 54 | 0.210 |
Why?
|
| Immunoconjugates | 1 | 2023 | 90 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 393 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2025 | 192 | 0.200 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2019 | 3 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 144 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 661 | 0.140 |
Why?
|
| Mutation | 1 | 2025 | 2607 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 707 | 0.100 |
Why?
|
| Aged | 4 | 2025 | 14278 | 0.060 |
Why?
|
| Young Adult | 2 | 2025 | 4646 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 310 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 5413 | 0.050 |
Why?
|
| Adult | 3 | 2025 | 16664 | 0.050 |
Why?
|
| Middle Aged | 3 | 2025 | 17410 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 335 | 0.050 |
Why?
|
| Registries | 1 | 2025 | 879 | 0.050 |
Why?
|
| Prognosis | 1 | 2025 | 1733 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2025 | 6556 | 0.040 |
Why?
|
| Humans | 5 | 2025 | 62934 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 103 | 0.040 |
Why?
|
| Male | 3 | 2025 | 29594 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 638 | 0.040 |
Why?
|
| Female | 3 | 2025 | 32587 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 863 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 242 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 5606 | 0.020 |
Why?
|